Clinical Trials | December 07, 2025
Bayer launches phase III trial testing Mirena for uterine condition with no treatments
NAEH can cause heavy or abnormal bleeding and, if left untreated, may progress to uterine cancer
NAEH can cause heavy or abnormal bleeding and, if left untreated, may progress to uterine cancer
Millions of stroke survivors across the world may soon have a new defense
HER2-mutant NSCLC typically has a poor prognosis and limited treatment options
Investigational cell therapy bemdaneprocel continues to demonstrate a favorable safety profile at 36 months in Phase I trial participants
The study also met all secondary endpoints with a reduction in severity of VMS at weeks 4 and 12, a reduction in frequency of VMS at week 1 as well as improvements in sleep disturbances and menopause related quality of life
Demonstrates vision gains with extended treatment intervals in retinal vein occlusion
At 24 months, data from the Phase 1 exPDite trial continue to show a favorable safety profile in all 12 participants in the trial’s high and low dose cohorts
Finerenone is the first mineralocorticoid receptor (MR) antagonist to demonstrate definitive cardiovascular benefits in a Phase III study in patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of ?40%
First patient enrolled in the Phase III SOHO-02 trial of investigational agent BAY 2927088 in treatment-naïve patients with advanced NSCLC with HER2-activating mutations
Finerenone significantly reduced the composite of cardiovascular death and total (first and recurrent) heart failure events compared to placebo in addition to usual therapy
Subscribe To Our Newsletter & Stay Updated
